6 results on '"Pensotti, C."'
Search Results
2. [Guidelines for management of community-acquired pneumonia in adults].
- Author
-
Lopardo G, Basombrío A, Clara L, Desse J, De Vedia L, Di Libero E, Gañete M, López Furst MJ, Mykietiuk A, Nemirovsky C, Osuna C, Pensotti C, and Scapellato P
- Subjects
- Adult, Aged, Anti-Bacterial Agents therapeutic use, Community-Acquired Infections diagnosis, Community-Acquired Infections drug therapy, Community-Acquired Infections epidemiology, Community-Acquired Infections microbiology, Humans, Middle Aged, Streptococcus pneumoniae, Pneumonia, Pneumococcal diagnosis, Pneumonia, Pneumococcal drug therapy, Pneumonia, Pneumococcal epidemiology, Pneumonia, Pneumococcal microbiology
- Abstract
Community-acquired pneumonia in adults is a common cause of morbidity and mortality particularly in the elderly and in patients with comorbidities. Most episodes are of bacterial origin, Streptococcus pneumoniae is the most frequently isolated pathogen. Epidemiological surveillance provides information about changes in microorganisms and their susceptibility. In recent years there has been an increase in cases caused by community-acquired meticillin resistant Staphylococcus aureus and Legionella sp. The chest radiograph is essential as a diagnostic tool. CURB-65 score and pulse oximetry allow stratifying patients into those who require outpatient care, general hospital room or admission to intensive care unit. Diagnostic studies and empirical antimicrobial therapy are also based on this stratification. The use of biomarkers such as procalcitonin or C-reactive protein is not part of the initial evaluation because its use has not been shown to modify the initial approach. We recommend treatment with amoxicillin for outpatients under 65 year old and without comorbidities, for patients 65 years or more or with comorbidities amoxicillin-clavulanic/sulbactam, for patients hospitalized in general ward ampicillin-sulbactam with or without the addition of clarithromycin, and for patients admitted to intensive care unit ampicillin-sulbactam plus clarithromycin. Suggested treatment duration is 5 to 7 days for outpatients and 7 to 10 for those who are hospitalized. During the influenza season addition of oseltamivir for hospitalized patients and for those with comorbidities is suggested.
- Published
- 2015
3. [Inter-society consensus for the management of respiratory infections: acute bronchitis and chronic obstructive pulmonary disease].
- Author
-
Lopardo G, Pensotti C, Scapellato P, Caberlotto O, Calmaggi A, Clara L, Klein M, Levy Hara G, López Furst MJ, Mykietiuk A, Pryluka D, Rial MJ, Vujacich C, and Yahni D
- Subjects
- Acute Disease, Argentina, Bronchitis diagnosis, Bronchitis microbiology, Dyspnea complications, Evidence-Based Medicine, Humans, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive microbiology, Risk Factors, Societies, Medical, Sputum microbiology, Anti-Bacterial Agents therapeutic use, Bronchitis drug therapy, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
The Argentine Society for Infectious Diseases and other national societies issued updated practical guidelines for the management of acute bronchitis (AB) and reactivations of chronic obstructive pulmonary disease (COPD) with the aim of promoting rational use of diagnostic and therapeutic resources. AB is a condition characterized by inflammation of the bronchial airways which affects adults and children without underlying pulmonary disease. It is usually caused by a virus. The diagnosis is based on clinical findings after community acquired pneumonia has been ruled out. Treatment of AB is mainly symptomatic. Antibiotics should be used in immune-compromised hosts, patients with chronic respiratory or cardiac diseases and in the elderly with co-morbidities. Reactivation of COPD is defined as an acute change in the patient's baseline clinical situation beyond normal day to day variations, with an increase in dyspnea, sputum production and/or sputum purulence, warranting a change in medication. An increase in one symptom is considered a mild exacerbation, two as moderate, and the presence of three symptoms is considered a severe exacerbation. An infectious agent can be isolated in sputum in 50 to 75% of COPD reactivations. Moderate and severe episodes must be treated with antibiotics, amoxicillin/ beta-lactamase inhibitor, macrolides and fluoroquinolones are first choice drugs.
- Published
- 2013
4. [Consensus guidelines for the management of upper respiratory tract infections].
- Author
-
Lopardo G, Calmaggi A, Clara L, Levy Hara G, Mykietiuk A, Pryluka D, Ruvinsky S, Vujacich C, Yahni D, Bogdanowicz E, Klein M, López Furst MJ, Pensotti C, Rial MJ, and Scapellato P
- Subjects
- Acute Disease, Argentina, Evidence-Based Medicine, Humans, Anti-Bacterial Agents therapeutic use, Otitis Media drug therapy, Pharyngitis drug therapy, Rhinitis drug therapy, Sinusitis drug therapy
- Abstract
Upper respiratory tract infections are the most common source of antibiotic prescriptions. Acute pharyngitis is caused mainly by viruses, viral cases can be distinguished from acute streptococcal pharyngitis using Centor clinical epidemiological criteria, by rapid antigen tests or throat culture. Treatment of choice for streptococcal infection is penicillin V given in two daily doses. In children, acute otitis media (AOM) is the infection for which antibiotics are most often prescribed. Predominant causative pathogens include Streptococcus pneumoniae, Haemophilus influenzae non-type b and Moraxella catarrhalis. Diagnosis is based on history, physical examination and otoscopic exam. Antibiotic treatment should be initiated promptly in all children<2 years of age, and in older children presenting bilateral AOM, otorrhoea, co-morbidities or severe illness. In Argentina, amoxicillin is the drug of choice given the low penicillin resistance rates for S. pneumoniae. In children who fail amoxicillin therapy, amoxicillin/clavulanate provides better coverage against beta-lactamase producing H. influenzae and M. catarrhalis. Rhinosinusitis is caused mainly by viruses, secondary bacterial complication occurs in less than 5% of cases. Diagnosis is based on physical examination and additional studies are not usually required. Acute bacterial sinusitis is caused by the same pathogens that cause AOM and amoxicillin is the drug of choice.
- Published
- 2012
5. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
- Author
-
Pensotti C, Nacinovich F, Vidiella G, Carbone E, Marin M, Di Stéfano C, and Stamboulian D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents economics, Arthritis, Infectious drug therapy, Arthroplasty adverse effects, Chronic Disease, Female, Humans, Male, Middle Aged, Osteomyelitis drug therapy, Prosthesis-Related Infections drug therapy, Retrospective Studies, Teicoplanin economics, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Bone Diseases, Infectious drug therapy, Joint Diseases drug therapy, Methicillin Resistance, Staphylococcal Infections drug therapy, Teicoplanin therapeutic use
- Abstract
We retrospectively evaluated 89 episodes of bone and joint infections due to methicillin-resistant staphylococci: 56 chronic osteomyelitis (CO), 10 septic arthritis (SA) and 23 infections associated to arthroplasties (IAA). We analyzed the efficacy of Teicoplanin (T) in three times a week or daily administration schemes and adequate surgery (AS). Also, we determined cost savings derived from outpatient parenteral antibiotic therapy (OPAT). The overall efficacy of T in CO and both in cases with and without implants, was higher when antibiotic therapy was associated to AS (86 vs. 46%, p = 0.001; 100 vs. 33%, p = 0.0049 and 76 vs. 50%, p = 0.09). All SA were cured. The overall efficacy of T was higher in IAA with implant removal vs. surgical debridement (100 vs. 54%, p = 0.045). In all cases, T was similarly effective when administered three times a week vs. daily administration, when associated to AS. The savings derived from OPAT were 897 days/bed and USS 179,400. Adverse effects were few and light (8 episodes, 9%). The results obtained are similar to those published in the literature and show that T administered daily or in a three times a week scheme and associated to AS, is effective and safe for the treatment of bone and joint infections. The savings derived from OPAT, mainly related to reduced hospitalization, are significant in these pathologies, which usually require long treatment periods.
- Published
- 2002
6. [Guidelines for the management of bone and joint infections due to methicillin resistant staphylococci].
- Author
-
Stamboulian D, Di Stefano C, Nacinovich F, Pensotti C, Marin M, and Carbone E
- Subjects
- Arthritis, Infectious diagnosis, Arthritis, Infectious etiology, Arthritis, Infectious therapy, Arthroplasty adverse effects, Arthroscopy adverse effects, Bone Diseases, Infectious diagnosis, Chronic Disease, Humans, Joint Diseases diagnosis, Osteomyelitis diagnosis, Osteomyelitis etiology, Osteomyelitis therapy, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections therapy, Staphylococcal Infections diagnosis, Bone Diseases, Infectious therapy, Joint Diseases therapy, Methicillin Resistance, Staphylococcal Infections therapy
- Abstract
Bone and joint infections are a group of complicated diseases with high morbidity. Emerging resistant microorganisms and the use of prosthetic devices have increased the difficulty in the medical treatment of patients. The purpose of these guidelines is to offer information on the management of bone and joint infections (post-invasive septic arthritis, chronic osteomyelitis and infected arthroplasty) produced by methicillin resistant staphylococci. They are oriented to physicians dedicated to internal medicine, infectious diseases, trauma and orthopedist surgeons as well as to everybody interested in this issue. The guidelines mainly point to the rational use of diagnostic methods and describe the new treatment modalities. A group of experts analyzed the different strategies for diagnosing and treating bone and joint infections due to methicillin resistant staphylococci and attempted at setting a level of evidence level and the strength of each recommendation.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.